Glenmark Pharma Inc. gets final approval from the USFDA

The United States Food & Drug Administration (USFDA) has given its final approval to Glenmark Pharmaceuticals Inc., USA (Glenmark), for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%.

Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5% is the generic version of Epiduo Gel, 0.1%|2.5% of Galderma Laboratories L.P. IQVIA reported that Epiduo Gel, 0.1%|2.5% was able to achieve annual sales of around US$33.7 million for the 12 month period ending September 2019.

Glenmark Pharmaceuticals Ltd. (GPL) is a research‐driven global integrated pharmaceutical organization. It is amongst the top pharma and biotech companies of the world in terms of the revenue. Glenmark is a leading company in the discovery of new molecules, NCEs (new chemical entity) and NBEs (new biological entity), both. It has various molecules in various stages of clinical development and is focused in the areas of oncology, dermatology, and respiratory.

On Monday, the stock of the company closed at Rs. 290.85, up by 1.48 per cent or Rs. 4.25 per share. The 52-week high is Rs. 706.90 and 52-week low is Rs. 269.75 on BSE.